Claims for Oral Anti-Cancer Drug Methotrexate (Revised)

Effective July 1, 2024, claims for Methotrexate (Jylamvo and Xatmep) with dates of service July 1, 2024, through September 30, 2024, shall be billed with HCPCS code J8999 (prescription drug, oral, chemotherapeutic, NOS) including adding a claim narrative to the line. Suppliers shall utilize J8999 until the October 2024 release and implementation of National Drug Code (NDC) cross walked HCPCS codes. Suppliers are currently billing for Methotrexate oral anti-cancer drugs to the Durable Medical Equipment Medicare Administrative Contactors (DME MACs) using the associated NDC. There are no changes to the policy requirements for these drugs.

Last Updated Sep 05 , 2024